Thomas Berg
Impact in
- Hepatology top 0.01%
- Hepatitis C virus research
- Hepatocellular Carcinoma Treatment and Prognosis
- Liver Disease and Transplantation
- Liver Diseases and Immunity
- Liver physiology and pathology
- Epidemiology top 0.02%
- Hepatitis B Virus Studies
- Liver Disease Diagnosis and Treatment
Papers in
- Hepatology 510
- Hepatitis C virus research 348
- Hepatocellular Carcinoma Treatment and Prognosis 61
- Liver Disease and Transplantation 54
- Liver Diseases and Immunity 33
- Liver physiology and pathology 27
- Epidemiology 259
- Hepatitis B Virus Studies 182
- Liver Disease Diagnosis and Treatment 77
- Co-authors
- Pietro Lampertico (18 shared papers)Maria Buti Ferret (17 shared papers)Harry L.A. Janssen (15 shared papers)Kosh Agarwal (4 shared papers)Fabien Zoulim (12 shared papers)Frank Tacke (16 shared papers)George Papatheodoridis (4 shared papers)Stefan Zeuzem (88 shared papers)
- Journals
- Journal of Hepatology (194 papers)Hepatology (65 papers)Gastroenterology (31 papers)Journal of Viral Hepatitis (24 papers)PLoS ONE (21 papers)
- Partner nations
- GermanyUnited StatesItaly
In The Last Decade
Thomas Berg
775 papers receiving 41.3k citations
Thomas Berg's Hit Papers
Peers
Comparison fields: 5 of 155
- Hepatology 19.9k
- Epidemiology 16.8k
- Immunology 1.2k
- Infectious Diseases 963
- Oncology 1.1k
Countries citing papers authored by Thomas Berg
This map shows the geographic impact of Thomas Berg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Berg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Berg more than expected).
Fields of papers citing papers by Thomas Berg
This network shows the impact of papers produced by Thomas Berg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Berg. The network helps show where Thomas Berg may publish in the future.
Co-authors
The 25 scholars most cited alongside Thomas Berg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 819 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection Hit paper breakdown → | 2017 | 4266 |
| 2 | IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy Hit paper breakdown → | 2009 | 1583 |
| 3 | Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis B Hit paper breakdown → | 2005 | 1252 |
| 4 | Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Hit paper breakdown → | 2019 | 1078 |
| 5 | Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study Hit paper breakdown → | 2010 | 955 |
| 6 | Vascular Invasion and Histopathologic Grading Determine Outcome After Liver Transplantation for Hepatocellular Carcinoma in Cirrhosis Hit paper breakdown → | 2001 | 772 |
| 7 | ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin for Hepatitis C with Cirrhosis Hit paper breakdown → | 2014 | 736 |
| 8 | Sofosbuvir and Velpatasvir for HCV Genotype 2 and 3 Infection Hit paper breakdown → | 2015 | 699 |
| 9 | A genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis Hit paper breakdown → | 2015 | 479 |
| 10 | The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm Hit paper breakdown → | 2014 | 416 |
| 11 | Update of the statements on biology and clinical impact of occult hepatitis B virus infection Hit paper breakdown → | 2019 | 414 |
| 12 | 2020 | 392 | |
| 13 | 2006 | 391 | |
| 14 | 2007 | 376 | |
| 15 | The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology Hit paper breakdown → | 2020 | 369 |
| 16 | 2005 | 354 | |
| 17 | 2007 | 331 | |
| 18 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 326 |
| 19 | 2004 | 323 | |
| 20 | Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores Hit paper breakdown → | 2020 | 305 |
About Thomas Berg
Thomas Berg is a scholar working on Hepatology, Epidemiology, Pathology and Forensic Medicine, Surgery and Infectious Diseases, having authored 819 papers that have together received 42.8k indexed citations. Recurring topics across this work include Hepatitis C virus research (348 papers), Hepatitis B Virus Studies (182 papers), Liver Disease Diagnosis and Treatment (77 papers), Hepatocellular Carcinoma Treatment and Prognosis (61 papers), Liver Disease and Transplantation (54 papers), Liver Diseases and Immunity (33 papers), Organ Transplantation Techniques and Outcomes (28 papers) and Liver physiology and pathology (27 papers). The work is most often cited by research in Hepatology (19.9k citations), Epidemiology (16.8k citations), Immunology (1.2k citations), Infectious Diseases (963 citations) and Oncology (1.1k citations). Thomas Berg has collaborated with scholars based in Germany, United States and Italy. Frequent co-authors include Pietro Lampertico, Maria Buti Ferret, Harry L.A. Janssen, Kosh Agarwal, Fabien Zoulim, Frank Tacke, George Papatheodoridis, Stefan Zeuzem, Florian van Bömmel and Ulrich Spengler. Their work appears in journals such as Journal of Hepatology, Hepatology, Gastroenterology, Journal of Viral Hepatitis and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.